Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG) - Summary - MDSpire
Clinical Guidelines

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)

This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent).

  • April 24, 2026

  • 7 min

Share

This phase III clinical trial, led by Andres Correa, MD, compares the effectiveness of gemcitabine in conjunction with intravesical Bacillus Calmette Guerin (BCG) versus BCG alone for patients suffering from recurrent non-muscle invasive bladder cancer. The study aims to determine if the addition of gemcitabine, a chemotherapy agent that impedes DNA production in cancer cells, enhances tumor destruction. Eligibility includes patients with specific histological confirmation of urothelial carcinoma, BCG-exposed NMIBC within a defined timeframe, and various other criteria regarding prior treatments and health status.

Original Source(s)

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)

  • April 24, 2026

Related Content

AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

An artificial intelligence (AI) multiagent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-...

Ulrich Steidl, MD, PhD, Named Director of Montefiore Einstein Comprehensive Cancer Center

An international leader in blood cancer and stem cell research has been named Director of the Montefiore Einstein Comprehensive Cancer Center and Vice President of Cancer Medicine at Montefiore Einste...

Dietary Influence on Leukemia and Lymphoma Progression

In 2015, LH, a 66-year-old female, was diagnosed with chronic lymphocytic leukemia (CLL), Rai stage 0. Untreated, the woman’s lymphocyte count rose from 5,000/mm3 to 16,000/mm3 in 6 years (doubling ti...